PNC Financial Services Group Inc. Has $777,000 Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

PNC Financial Services Group Inc. raised its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 6.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 58,709 shares of the company’s stock after purchasing an additional 3,392 shares during the period. PNC Financial Services Group Inc.’s holdings in Takeda Pharmaceutical were worth $777,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Smithfield Trust Co boosted its position in shares of Takeda Pharmaceutical by 76.9% during the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock valued at $49,000 after buying an additional 1,490 shares during the last quarter. Sage Rhino Capital LLC lifted its stake in Takeda Pharmaceutical by 14.9% during the 4th quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company’s stock valued at $157,000 after acquiring an additional 1,538 shares in the last quarter. Kovitz Investment Group Partners LLC boosted its holdings in Takeda Pharmaceutical by 7.0% during the 3rd quarter. Kovitz Investment Group Partners LLC now owns 25,456 shares of the company’s stock worth $362,000 after acquiring an additional 1,670 shares during the last quarter. Aaron Wealth Advisors LLC grew its stake in shares of Takeda Pharmaceutical by 7.2% in the 4th quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company’s stock worth $331,000 after acquiring an additional 1,670 shares in the last quarter. Finally, Versant Capital Management Inc purchased a new stake in shares of Takeda Pharmaceutical in the fourth quarter valued at about $26,000. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Stock Up 1.1 %

Takeda Pharmaceutical stock opened at $15.18 on Tuesday. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.58 and a fifty-two week high of $15.24. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The firm’s 50-day simple moving average is $13.80 and its 200 day simple moving average is $13.90. The stock has a market cap of $48.29 billion, a PE ratio of 37.94, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.